Back to Stakeholders
CaaMTech is a US psychedelic drug discovery company based in Issaquah, Washington, focused on novel tryptamine chemistry. Founded around 2018, the company raised $22M in a 2021 Series A and holds a CRADA with NIH/NIDA and a research collaboration with UMass Dartmouth. Its two flagship compound series are Prophoria™ (4-AcO-DMT analogues) and Amphoria™ (4-HO-MiPT analogues), which the company is developing as improved psychedelic therapeutics with potentially more targeted and safer profiles than existing compounds.
Drug Pipeline
2Prophoria™ series (4-AcO-DMT analogues)
Pre-clinical
Novel 4-AcO-DMT analogue series in preclinical development; NIDA CRADA and UMass Dartmouth collaboration.
Amphoria™ series (4-HO-MiPT analogues)
Pre-clinical
Novel 4-HO-MiPT analogue series in preclinical development; part of a broader tryptamine chemistry platform with 7 patents.
Quick Facts
- Type
- Private Biotech
- Founded
- 2018
- Lead Stage
- Pre-clinical
- Website
- Visit